U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07344376) titled 'An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)' on Nov. 17, 2025.
Brief Summary: The objective of this study is to assess the long-term safety and efficacy of Hunterase for approximately 1 year in subjects who completed the end of study (EOS) visit (Visit 54) tests in the Phase 3 Hunterase study and patients who received Hunterase for more than 6 months
Study Start Date: May 23, 2018
Study Type: INTERVENTIONAL
Condition:
MPS II
Hunter Syndrome (MPS II)
Hunter Syndrome
Hunterase
GC1111
Intervention:
DRUG: Hunterase
0.5mg/kg weekly IV administration
Recruitment Status: COMPLETED...